Top

BMC Health Services Research

Published in:

Open Access 01-12-2014 | Research article

Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings

Authors: Suvimol Niyomnaitham, Andrew Page, Adam La Caze, Karen Whitfield, Alesha J Smith

Published in: BMC Health Services Research | Issue 1/2014

Abstract

Background

A see on cardiovascular diseases and bladder cancer. The changes to the patterns of rosiglitazone and pioglitazone utilisation in Australia following the timing of these various health authority warnings such as the Australian Therapeutic Good Administration (TGA), European Medicines Agency (EMA) press releases or U.S. Food and Drug Administration (FDA) is unknown. This study investigated the utilisation patterns of rosiglitazone and pioglitazone in Australia before and after warnings of major drug authorities.

Methods

We evaluated rosiglitazone and pioglitazone dispensing using the Pharmaceutical Benefit Scheme (PBS) subsidised drug dispensing data for the Australian population from February 2004 to July 2012. The World Health Organisation Anatomic Therapeutic Chemical (ATC)/Defined Daily Dose (DDD) system was used to compare the drug utilisation patterns following the announcements of EMA, FDA, and TGA safety warnings, which first occurred in May 2007. The DDD/1000population/day were examined in a series of time-series regression analysis with the drug safety warnings specified as interventions.

Results

Rosiglitazone utilisation increased steadily from 2004 until reaching a peak at 1.96/1000population/day in January 2007. Then rosiglitazone use decreased significantly after the initial EMA press release and FDA warning on cardiovascular risk in May 2007 (with a 15.04% average monthly decline, p-value <0.001), however use did not significantly decrease after the TGA warning or subsequent EMA and FDA warnings. Pioglitazone utilisation proceeded rosiglitazone in September 2008 and remained above 1.5/1000/day during 2009–2010. However, pioglitazone utilisation has slightly declined after the FDA, EMA, and TGA warnings related to bladder cancer.

Conclusions

Drug safety warnings were associated with a decrease in rosiglitazone and pioglitazone utilisation in Australia. Rosiglitazone began to decline prior to TGA warnings in December 2007, which suggests that Australian prescribers may have acted in response to scientific evidence or international safety warnings (EMA, FDA), prior to the response of the TGA. Minor effects were observed after bladder cancer warnings on pioglitazone utilisation.

Available only for authorised users

Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A: Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001, 24 (2): 308-315. 10.2337/diacare.24.2.308.CrossRefPubMed

Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose–response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000, 23 (11): 1605-1611. 10.2337/diacare.23.11.1605.CrossRefPubMed

Pharmaceutical benefit scheme medicine listing. Department of Health and Ageing. Australian Government. Available from: http://www.pbs.gov.au/browse/medicine-listing. (accessed December 20, 2012)

Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007, 356 (24): 2457-2471. 10.1056/NEJMoa072761.CrossRefPubMed

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ: Rosiglitazone evaluated for cardiovascular outcomes–an interim analysis. N Engl J Med. 2007, 357 (1): 28-38. 10.1056/NEJMoa073394.CrossRefPubMed

Bilik D, McEwen LN, Brown MB, Selby JV, Karter AJ, Marrero DG, Hsiao VC, Tseng CW, Mangione CM, Lasser NL, Crosson JC, Herman WH: Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD). Pharmacoepidemiol Drug Saf. 2010, 19 (7): 715-721. 10.1002/pds.1954.CrossRefPubMedPubMedCentral

Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S: A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf. 2007, 16 (10): 1065-1071. 10.1002/pds.1470.CrossRefPubMed

FDA: Briefing Information for the July 13–14, 2010 Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm218491.htm. (accessed April 6, 2014)

Weatherby LB, Nordstrom BL, Fife D, Walker AM: The impact of wording in “Dear doctor” letters and in black box labels. Clin Pharmacol Ther. 2002, 72 (6): 735-742. 10.1067/mcp.2002.129503.CrossRefPubMed

10.

FDA: Advisory Committee. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218493.pdf. (accessed April 6, 2014)

11.

Therapeutic Goods Administralion. About the TGA. Available from: http://www.tga.gov.au/about/committees-acsom.htm. (accessed May 30, 2012)

12.

FDA: Drug Safety Communication. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm199082.htm. (accessed Dec 20, 2012)

13.

European Medicines Agency: News, press release and public statement archive. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/landing/news_search_landing_page.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1. (accessed on Nov 12, 2012)

14.

PBS Latest News. Changes to listings for ROSIGLITAZONE MALEATE (Avandia®) and ROSIGLITAZONE MALEATE with METFORMIN HYDROCHLORIDE (Avandamet®)-1 November 2008. Available from: http://www.pbs.gov.au/info/news/2008/11/List-amndmnts-avandia-avandamet (accessed May 10, 2012)

15.

Pharmaceutical Benefits Advisory Committee. Positive Recommendations made by the PBAC — March 2011. 2011, Canberra: Australian Government Department of Health and Ageing, Available from: http://www.pbs.gov.au/info/publication/factsheets/professional/new-listings-and-changes-1-july-2011 (accessed April 6, 2014)

16.

Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007, 298 (10): 1180-1188. 10.1001/jama.298.10.1180.CrossRefPubMed

17.

Erdmann E, Spanheimer R, Charbonnel B: Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). J Diabetes. 2010, 2 (3): 212-220. 10.1111/j.1753-0407.2010.00082.x.CrossRefPubMed

18.

AFSSAPS. Available from: http://ansm.sante.fr/var/ansm_site/storage/original/application/3b70d267800de891b8f204f0376b7538.pdf. (accessed May 30, 2012)

19.

Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP, Vaughn DJ, Nessel L, Selby J, Strom BL: Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011, 34 (4): 916-922. 10.2337/dc10-1068.CrossRefPubMedPubMedCentral

20.

Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD: Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst. 2012, 104 (18): 1411-1421. 10.1093/jnci/djs328.CrossRefPubMedPubMedCentral

21.

European Medicines Agency: Press release. European Medicines Agency recommends new contraindications and warnings for pioglitazone to reduce small increassed risk of bladder cancer. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/07/WC500109176.pdf. (accessed May 30, 2012)

22.

TGA: Pioglitazone and risk of bladder cancer. Safety advisory. Available from: http://www.tga.gov.au/safety/alerts-medicine-pioglitazone-110718.htm. (accessed Dec 12, 2012)

23.

FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm. (accessed Dec 20, 2012)

24.

Starner CI, Schafer JA, Heaton AH, Gleason PP: Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm. 2008, 14 (6): 523-531.PubMed

25.

Cohen A, Rabbani A, Shah N, Alexander GC: Changes in glitazone use among office-based physicians in the U.S., 2003–2009. Diabetes Care. 2010, 33 (4): 823-825. 10.2337/dc09-1834.CrossRefPubMedPubMedCentral

26.

Stewart KA, Natzke BM, Williams T, Granger E, Casscells SW, Croghan TW: Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone. Pharmacoepidemiol Drug Saf. 2009, 18 (11): 1048-1052. 10.1002/pds.1819.CrossRefPubMed

27.

Ruiter R, Visser LE, van Herk-Sukel MP, Geelhoed-Duijvestijn PH, Bie SD, Straus SM, Mol PG, Romio SA, Herings RM, Stricker BH: Prescribing of Rosiglitazone and Pioglitazone Following Safety Signals: Analysis of Trends in Dispensing Patterns in the Netherlands from 1998 to 2008. Drug Saf. 2012, 35 (6): 471-480. 10.2165/11596950-000000000-00000.CrossRefPubMed

28.

WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. Available from: http://www.whocc.no/atc_ddd_index/. (accessed Nov 23, 2011)

29.

Australian Goverment Department of Health and Ageing. About PBS. Available from: http://pbs.gov.au/info/about-the-pbs (accessed November 30, 2011)

30.

Hollingworth S, Duncan EL, Martin JH: Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf. 2010, 19 (10): 1019-1024. 10.1002/pds.1969.CrossRefPubMed

31.

Islam MM, Conigrave KM, Day CA, Nguyen Y, Haber PS: Twenty-year trends in benzodiazepine dispensing in the Australian population. Intern Med J. 2014, 44 (1): 57-64. 10.1111/imj.12315.CrossRefPubMed

32.

Centrelink. Department of Human Services. Australian Government. Available from: http://www.humanservices.gov.au/. (accessed July 20, 2012)

33.

Australian Bureau of Statistics. Available from: http://www.abs.gov.au/. (accessed July 20, 2012)

34.

TGA: Safety information. Available from: http://www.tga.gov.au/hp/information-safety.htm. (accessed Dec 12, 2012)

35.

European Medicines Agency: News and events. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/landing/news_and_events.jsp&mid=. (accessed May 30, 2012)

36.

Food and Drug Administation: Drug Safety Communications. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm199082.htm. (accessed May 30, 2012)

37.

TGA: Australian Adverse Drug Reactions Bulletin, Vol 26, No 6. Available from: http://www.tga.gov.au/hp/aadrb-0712.htm. (accessed Dec 20, 2012)

38.

TGA: Safety information. Rosiglitazone (Avandia/Avandamet). Advisory statement. Available from: http://www.tga.gov.au/safety/alerts-medicine-rosiglitazone-100924.htm. (accessed Nov 20, 2012)

39.

FDA: Postmarket Drug Safety Information for Patients and Providers. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm143349.htm. (accessed Dec 20, 2012)

40.

FDA Drug Safety Communication. FDA Issues Safety Alert on Avandia. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/2007/ucm108917.htm. (accessed April 6, 2014)

41.

FDA: Avandia label. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM143413.pdf. (accessed Dec 20, 2012)

42.

FDA significant restricts access to the diabetes drug Avandia. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm226956.htm. (accessed Dec 20, 2012)

43.

European Medicines Agency: Press release on May 23, 2007. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500013467.pdf. (accessed May 15, 2011)

44.

European Medicines Agency: Press release on October 18, 2007. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500011009.pdf. (accessed May 15, 2011)

45.

European Medicines Agency: Press release on January 24, 2008. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015420.pdf. (accessed May 15, 2012)

46.

European Medicines Agency: European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&mid=WC0b01ac058004d5c1&jsenabled=true. (accessed May 30, 2012)

47.

Box GEP TG: Intervention analysis with applications to economic and environmental problems. J Am Stat Assoc. 1975, 70: 70-74. 10.1080/01621459.1975.10480264.CrossRef

48.

Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA: Responding to an FDA warning–geographic variation in the use of rosiglitazone. N Engl J Med. 2010, 363 (22): 2081-2084. 10.1056/NEJMp1011042.CrossRefPubMed

49.

Hurren KM, Taylor TN, Jaber LA: Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert. Diabetes Res Clin Pract. 2011, 93 (1): 49-55. 10.1016/j.diabres.2011.02.035.CrossRefPubMed

50.

Australian Government Department of Health and Ageing: March 2008 PBAC Outcomes — Positive Recommendations made by the PBAC-November 2008. Available from: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes/2008-11/positive-recommendations (accessed May 30, 2012)

51.

Leal I, Romio SA, Schuemie M, Oteri A, Sturkenboom M, Trifiro G: Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone. Br J Clin Pharmacol. 2013, 75 (3): 861-868.PubMedPubMedCentral

52.

Kostapanos MS, Elisaf MS, Mikhailidis DP: Pioglitazone and cancer: angel or demon?. Curr Pharm Des. 2012, 19 (27): 4913-4929.CrossRef

53.

Buckley NA, Rossi S: Bringing greater transparency to “black box” warnings. Clin Toxicol (Phila). 2011, 49 (6): 448-451. 10.3109/15563650.2011.593523.CrossRef

54.

Esterly JS, Steadman E, Scheetz MH: Impact of the FDA warning of potential ceftriaxone and calcium interactions on drug use policy in clinical practice. Int J Clin Pharm. 2011, 33 (3): 537-542. 10.1007/s11096-011-9503-4.CrossRefPubMed

55.

Sen EF, Verhamme KM, Felisi M, t Jong GW, Giaquinto C, Picelli G, Ceci A, Sturkenboom MC: Effects of safety warnings on prescription rates of cough and cold medicines in children below 2 years of age. Br J Clin Pharmacol. 2011, 71 (6): 943-950. 10.1111/j.1365-2125.2010.03860.x.CrossRefPubMedPubMedCentral

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6963/14/151/prepub

Title: Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings
Authors: Suvimol Niyomnaitham
Andrew Page
Adam La Caze
Karen Whitfield
Alesha J Smith
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Health Services Research / Issue 1/2014
Electronic ISSN: 1472-6963
DOI: https://doi.org/10.1186/1472-6963-14-151

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Effect of a care transition intervention by pharmacists: an RCT

A comparison of drugs and procedures of care in the Italian hospice and hospital settings: the final three days of life for cancer patients

Field methods in medical record abstraction: assessing the properties of comparative effectiveness estimates

Living with diabetes: a group-based self-management support programme for T2DM patients in the early phases of illness and their partners, study protocol of a randomised controlled trial

Continuity of GP care is associated with lower use of complementary and alternative medical providers: a population-based cross-sectional survey

Hospital bed occupancy for rotavirus and all cause acute gastroenteritis in two Finnish hospitals before and after the implementation of the national rotavirus vaccination program with RotaTeq®